Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

At their Annual Meeting 13 Sept, the Trustees of the Royal Society of Tropical Medicine and Hygiene (RSTMH) awarded MORU’s Dr Direk Limmathurotsakul its Emerging Leaders Award.

Awarded annually, the RSTMH Emerging Leaders Award recognises significant contributions in leadership and service, including mentoring and other forms of capacity-building, to the fields of tropical medicine and global health by early-career investigators based in low and middle-income countries.

Based in Bangkok and Head of Microbiology at MORU, Direk is an Assistant Professor at the Faculty of Tropical Medicine at Mahidol University in Thailand and a Wellcome Trust Intermediate Fellow in Public Health and Tropical Medicine.

“I would like to thank my colleagues Susanna Dunachie and Nick Day who nominated me and presented the citation at the meeting. I very much appreciate their kindness and support,” said Direk at the Awards ceremony.

Recognised as a world expert on melioidosis, an infectious disease caused by Burkholderia pseudomallei, Direk has published more than 100 publications on melioidosis over the past decade and led a series of laboratory and clinical studies demonstrating for the first time that ingestion and inhalation are important infection routes for melioidosis in northeast Thailand.

Direk also developed the first evidence-based guidelines for the prevention of melioidosis for people living in endemic areas and recently published a landmark melioidosis paper, estimating the global burden of melioidosis, in Nature Microbiology 2016. He mapped all documented human and animal cases, and the presence of environmental B. pseudomallei, and combined this in a formal modelling to estimate the global burden of melioidosis. He estimated there to be 165,000 human melioidosis cases per year worldwide, of which 89,000 die.

A lead researcher in antimicrobial resistance in Southeast Asia, Direk’s on-going research includes antibiotic use in animals, estimating the burden of antimicrobial-resistant infections in Southeast Asia, and identifying where resources are most needed to fight effectively against antimicrobial resistance in low and middle-income countries.

Similar stories

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU Bangkok Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Susie Dunachie awarded flagship NIHR career development award

Awards & Appointments MORU Bangkok

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU Bangkok Research

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

MORU Bangkok Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.

Clare Ling awarded honorary FRCPath

Awards & Appointments SMRU

Dr Clare Ling has been made an honorary Fellow of the Royal College of Pathologists (FRCPath). Currently running Shoklo Malaria Research Unit (SMRU) Microbiology department and supporting the unit’s molecular activities, Clare is a clinical scientist who has worked at SMRU on the Thai-Myanmar border since 2012.

Applicability of COVID-19 vaccine trial results to low-and-middle-income countries

COVID-19 MORU Bangkok

In the next few months, the first Phase 3 COVID-19 vaccine trials – the majority of them in upper-middle or high-income countries and in specific target populations like young adults – will report their results. How relevant will their study results be for low-resource settings?